Associated Papers
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.
Pavlova S et al.
Hemasphere, 2025
39840379 (PubMed )
Supplement: HEM3-9-e70065-s001.xlsx › Table_S5
Expanding Broad Molecular Reflex Testing in Non-Small Cell Lung Cancer to Squamous Histology.
Zacharias M et al.
Cancers, 2024
38473263 (PubMed )
Supplement: cancers-16-00903-s001.zip › TableS2.xlsx › Tabelle
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
37304756 (PubMed )
Supplement: zcad025_supplemental_files.zip › Supplementary_Table_2.xlsx › PVs
Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level.
Nakamura IT et al.
Cancer Science, 2021
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
Gröschel S et al.
Nature Communications, 2019
30967556 (PubMed )
Supplement: 41467_2019_9633_MOESM3_ESM.xlsx › Indels
NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L et al.
International Journal of Cancer, 2016
26340530 (PubMed )
Supplement: IJC-138-927-s005.xlsx › Tabelle1
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W et al.
Nature Genetics, 2013
24185512 (PubMed )
Supplement: NIHMS531250-supplement-2.xlsx › All_samples_N_36_
Select a paper to view details